Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 28 (1) , 930-942
Abstract
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a potent anticancer drug with versatile biological activities, while the clinical translation of curcumin is severely limited due to its hydrophobicity, rapid elimination, and metabolism in the blood circulation. Herein, we aim to unravel the potential of curcumin as a synergistic agent with immunotherapy in the treatment of cancers. In an effort to minimize premature release and improve the systemic bioavailability, a superior blood stable and reduction sensitive curcumin micellar formulation, of which the release can be triggered by cancer cells, is rationally designed. We have synthesized a telodendrimer (mPEG-PLA-(LA)4) capable of forming reversible disulfide crosslinked micelles (DCMs). The curcumin loaded DCMs (Cur/DCMs) are spherical with a uniform size of 24.6 nm. The in vitro release profile demonstrates that curcumin releases significantly slower from DCMs than that from non-crosslinked micelles (NCMs), while the release can be accelerated with the increasing concentration of reducing agent glutathione (GSH). Intravenous administration of Cur/DCMs stably retains curcumin in the bloodstream and efficiently improves the systemic bioavailability. Furthermore, Cur/DCMs exhibit synergistic anticancer efficacy when combined with the anti-PD-1 antibody in an MC-38 colon cancer xenograft model. Our results potentiate the integration of blood stable curcumin nanoformulation and immunotherapy for cancer treatment.Keywords
Funding Information
- National Natural Science Foundation of China (32070774, 31800840)
- Science and Technology Program of Guangzhou (202002030486)
- Key Research & Development Program of Bioland Laboratory (2018GZR110104002)
This publication has 42 references indexed in Scilit:
- Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodiesEuropean Journal of Cancer, 2013
- Curcumin Induces the Differentiation of Myeloid-Derived Suppressor Cells and Inhibits Their Interaction with Cancer Cells and Related Tumor GrowthCancer Prevention Research, 2012
- Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel deliveryBiomaterials, 2011
- Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer TreatmentMolecules, 2011
- Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseasesThe International Journal of Biochemistry & Cell Biology, 2009
- Method for Analysis of Nanoparticle Hemolytic Properties in VitroNano Letters, 2008
- Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibitionGut, 2008
- Curcumin: The story so farEuropean Journal of Cancer, 2005
- Curcumin and Genistein, Plant Natural Products, Show Synergistic Inhibitory Effects on the Growth of Human Breast Cancer MCF-7 Cells Induced by Estrogenic PesticidesBiochemical and Biophysical Research Communications, 1997
- Amino‐termined poly(L‐lactide)s as initiators for the polymerization of N‐carboxyanhydrides: synthesis of poly(L‐lactide)‐block‐poly(α‐amino acid)sMacromolecular Chemistry and Physics, 1995